RecruitingNCT03460769

Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)

Sponsor

M.D. Anderson Cancer Center

Enrollment

775 participants

Start Date

Apr 1, 2021

Study Type

OBSERVATIONAL

Conditions

Pancreatic Cancer Chronic Pancreatitis Diabetes Mellitus Type 3c

Summary

The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT), which is part of the NIH U01 funded Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC). Similar to all studies that will be coordinated and managed by the CDMC, no patient enrollment will occur at MDACC. All patient recruitment will occur at external sites that are a part of the CPDPC, which are listed in the appended DETECT protocol. The data management systems, auditing, and monitoring effort are supported by the CDMC.

Eligibility

Min Age: 30 YearsMax Age: 84 Years

Plain Language Summary

Simplified for easier understanding

This study (called DETECT) is evaluating a special liquid meal test to better diagnose a type of diabetes that develops because of pancreatic disease — such as pancreatic cancer or chronic pancreatitis — distinguishing it from more common type 2 diabetes. **You may be eligible if...** - You are between 30 and 84 years old - You fall into one of several groups: newly or long-standing diagnosed with diabetes related to pancreatic cancer, chronic pancreatitis, or standard type 2 diabetes; or you have pancreatic cancer or chronic pancreatitis without diabetes; or you are a healthy control **You may NOT be eligible if...** - You have another serious illness that your doctor believes would make participation too risky - Your diabetes is too unstable to safely pause diabetes medications for the test - You take very high doses of insulin (over 0.75 units/kg/day) - You have been hospitalized for acute pancreatitis in the past 2 months - You have had previous pancreatic surgery (including a Whipple procedure or total removal of the pancreas) - You have a type of pancreatic cancer other than adenocarcinoma (e.g., pancreatic neuroendocrine tumors) - You are currently taking oral steroids Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERData Management and Monitoring

The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT), which is part of the NIH U01 funded Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC).